首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism
【24h】

Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism

机译:两年的盐酸西那卡塞治疗降低了继发于甲状旁腺功能亢进的血液透析患者的甲状旁腺体积和血清甲状旁腺激素水平

获取原文
获取原文并翻译 | 示例
           

摘要

The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT). The present study was a prospective observational study to determine the effect of cinacalcet treatment on PTG volume and serum biochemical parameters in 60 patients with renal SHPT, already treated with intravenous vitamin D receptor activator (VDRA). Measurement of biochemical parameters and PTG volumes were performed periodically, which were analyzed by stratification into tertiles across the baseline parathyroid hormone (PTH) level or PTG volume. We also determined the factors that can estimate the changes in PTG volume and the achievement of the target PTH range by multivariable analyses. Two years of cinacalcet treatment significantly decreased the serum levels of PTH, calcium, and phosphate, followed by the improvement of achieving the target ranges for these parameters recommended by the Japanese Society for Dialysis Therapy. Cinacalcet decreased the maximal and total PTG volume by about 30%, and also decreased the serum PTH level independent of the baseline serum PTH level and PTG volume. Ten out of 60 patients showed 30% increase in maximal PTG after 2 years. Multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at two years. In conclusion, cinacalcet treatment with intravenous VDRA therapy decreased both PTG volume and serum intact PTH level, irrespective of the pretreatment PTG status and past treatment history.
机译:在中至晚期继发性甲状旁腺功能亢进症(SHPT)患者中,很少研究盐酸西那卡塞对甲状旁腺(PTG)量的长期影响。本研究是一项前瞻性观察性研究,旨在确定西那卡塞治疗对60例已经接受静脉注射维生素D受体激活剂(VDRA)治疗的肾SHPT患者的PTG量和血清生化指标的影响。定期进行生化参数和PTG量的测量,然后通过将其分为基线甲状旁腺激素(PTH)水平或PTG量分层成三分位数进行分析。我们还确定了可以通过多变量分析估算PTG量变化和目标PTH范围实现的因素。西那卡塞治疗两年后,血清PTH,钙和磷酸盐水平显着降低,随后改善了达到日本透析治疗协会推荐的这些参数的目标范围。西那卡塞降低了最大和总PTG量约30%,并且还降低了血清PTH水平,与基线血清PTH水平和PTG体积无关。 60名患者中有10名在2年后显示最大PTG增加了30%。多变量分析显示,基线时结节性PTG患者和1年时血清钙和PTH水平较高的患者很可能超过两年时PTH的目标范围。总之,西那卡塞静脉注射VDRA治疗可降低PTG量和血清完整PTH水平,而与治疗前PTG的状态和既往治疗史无关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号